MARK BUSH: Open Payments
NPI 1730733783 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$14,238 in 72 payments from 12 companies in 2025. Trend: 2023 $14,613 · 2024 $19,279 · 2025 $14,238
Speaker / faculty: $13,200Food & beverage: $837Travel & lodging: $194Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $13,587 |
| Supernus Pharmaceuticals, Inc. | 30 | $160 |
| Janssen Pharmaceuticals, Inc | 1 | $121 |
| Neurocrine BioSciences, Inc. | 1 | $106 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Lundbeck LLC | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $31 |
| Alkermes, Inc. | 2 | $29 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $20 |
Products named: VRAYLAR, Qelbree, SPRAVATO, INGREZZA, Auvelity, REXULTI, FANAPT, LYBALVI.
Industry payments across KY — which companies pay providers there.
